about
Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncopeImplantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncopeMechanism of hypotensive transients associated with abrupt bradycardias in conscious rabbitsPrognostic differences between atrial fibrillation and atrial flutter.Syncope risk stratification tools vs clinical judgment: an individual patient data meta-analysis.Statistical issues encountered in the comparison of health-related quality of life in diseased patients to published general population norms: problems and solutions.Role of pacing in the treatment of vasovagal syncope.Putting it together: a new treatment algorithm for vasovagal syncope and related disorders.Cost-utility analysis of pacemakers for the treatment of vasovagal syncope.Pacing to prevent vasovagal syncope.Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.Usefulness of clinical factors in predicting outcomes of passive tilt tests in patients with syncope.The relationship between health-related quality of life and frequency of spells in patients with syncope.Components of clinical trials for vasovagal syncope.A randomized study of tilt test angle in patients with undiagnosed syncope.Permanent cardiac pacing to prevent vasovagal syncope.Precordial QT dispersion does not predict inducibility of ventricular tachyarrhythmias at post-revascularization electrophysiologic study.Historical criteria that distinguish syncope from seizures.Syncope: investigation and treatment.Role of pacemakers in treating neurocardiogenic syncope.Outcome of patients with dual-chamber pacemakers implanted for the prevention of neurally mediated syncope.Learning needs of patients with vasovagal syncope.Second Vasovagal Pacemaker Study (VPS II): rationale, design, results, and implications for practice and future clinical trials.Methodology of isoproterenol-tilt table testing in patients with syncope.Management of vasovagal syncope: 2004.Tilt testing for syncope: a reappraisal.Reproducibility of isoproterenol tilt-table tests in patients with syncope.Diagnostic criteria for vasovagal syncope based on a quantitative history.Age of first faint in patients with vasovagal syncope.Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope.The Second Prevention of Syncope Trial (POST II)--a randomized clinical trial of fludrocortisone for the prevention of neurally mediated syncope: rationale and study design.Vasovagal syncope in medical students and their first-degree relatives.Worsening of symptoms before presentation with vasovagal syncope.Current concepts in the evaluation and management of syncope.Evidence-based treatment for vasovagal syncope.Vasovagal syncope: state or trait?Design and use of a quantitative scale for measuring presyncope.Effect of metoprolol on quality of life in the Prevention of Syncope Trial.The development and preliminary validation of a scale measuring the impact of syncope on quality of life.Metastatic melanoma to the heart presenting with ventricular tachycardia.
P50
Q24185889-F047FE06-3E82-41BD-B915-C0319984E375Q24186831-972F8696-8021-4BE7-9EA2-8F95492FE634Q30490642-EAA89AC8-210A-4D7A-B068-FD6360E7FCB6Q30756956-AEB6A656-622B-402A-BC34-9D6EBD7AC348Q30826820-0929F77F-3A05-42AF-B4D1-28B9EF09DB1CQ33144773-4FE6C3D7-36EA-410D-8821-FFC17640AA6FQ33145118-BFE238FA-B9E6-4AAD-A20B-1D70149253B0Q33145120-6D41D12D-48E9-4E4F-8FD8-37F078217B0FQ33145190-8F26877B-D747-42BB-ABE5-6D8B4BF9DBBAQ33145324-43EEF57C-ED0C-4C97-A973-0931C1569009Q33145337-F842C7B1-593D-440B-947C-7E6107E06AA9Q33145887-A0C39120-9331-4FEA-9403-38A1F83AC081Q33146029-9EFB3C91-B2CF-43D9-986B-D8DA2D9AA572Q33146629-4BD56A34-8242-4BA5-87AB-08440B5A000EQ33147018-71E067E0-C18E-4A17-9192-54BF3032888BQ33147246-5C3E9665-A4D4-4144-999E-DA0AF2EE3E5AQ33147358-22FCFBAC-DB5F-41F0-9C8C-B1F1FEAEC6A6Q33147868-8BC65680-2660-4A0F-B493-C6AD42AED1FCQ33147994-B8C6D324-E753-4804-9866-76780F3CA189Q33148430-CAFF142E-486C-47E5-A971-F602942D3511Q33148649-95E272DC-4074-4636-8369-2EE995075462Q33148848-A210AFFD-214E-46D1-BD65-A06CEB5FFCDFQ33151255-EC44F444-AA05-4D5A-8E46-C35B68A41F8EQ33151849-E7760BED-7977-41B9-9EE2-D8635FD90535Q33151984-B9470545-CE95-4DCE-AED4-59C1765D3AC2Q33152147-52F32D27-2472-4FB1-96F7-B900E06AFB8AQ33152604-26279829-082A-4646-AA93-E3ED1494CC49Q33153167-E1B4D6E0-7BAE-460B-9D27-7C51449D7BBEQ33153503-684ED538-6E97-4A1F-A72B-AF9A9E9A98B2Q33153607-6084B737-A7C8-4E7C-B17C-D87372A81641Q33153947-2C1EC8B0-9DB7-4FF5-9874-1315449A4CAFQ33154054-83CCC473-009F-44EC-A4AE-3C3BCBD87770Q33155387-79756C97-A1DA-47EC-B7A9-9B1586F83048Q33156559-EACBA799-ACC2-43D0-837F-207B1BE34AFBQ33156797-55FFA8F1-57D2-4B6A-BE90-5C68C331304BQ33156952-D17A98B4-92E8-4EFA-9C3E-3486B82E46C6Q33157292-005E5291-50DF-4F30-8F1B-E49A9A55A978Q33157531-285EAAD5-7B66-4994-A62F-3F28040269A4Q33157888-BB4AD07C-5178-49B5-994E-CF78DB78F399Q33158429-B6E71240-C2F9-4C53-806F-76F0DA3940B8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Robert Stanley Sheldon
@ast
Robert Stanley Sheldon
@en
Robert Stanley Sheldon
@es
Robert Stanley Sheldon
@nl
Robert Stanley Sheldon
@sl
type
label
Robert Stanley Sheldon
@ast
Robert Stanley Sheldon
@en
Robert Stanley Sheldon
@es
Robert Stanley Sheldon
@nl
Robert Stanley Sheldon
@sl
altLabel
R S Sheldon
@en
R Sheldon
@en
R. S. Sheldon
@en
R. Sheldon
@en
Robert S Sheldon
@en
Robert S. Sheldon
@en
prefLabel
Robert Stanley Sheldon
@ast
Robert Stanley Sheldon
@en
Robert Stanley Sheldon
@es
Robert Stanley Sheldon
@nl
Robert Stanley Sheldon
@sl
P214
P244
P106
P21
P214
P244
P31
P734
P735
P7859
lccn-n99804284